The cell line is not submitted yet.
(only basic data is shown)
General
Cell Line |
|
| hPSCreg name | SCTi003-A-2 |
| Cite as: | SCTi003-A-2 |
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 22nd August 2025 |
| Notes | Genome-edited Human hiPSC Line, SCTi003-A-2, APP K670N/M671L (Swedish Mutation) (SCTi003-A-2) was generated by CRISPR/Cas9 technology, which introduced the amyloid precursor protein (APP) K670N/M671L double mutation (also known as the Swedish mutation, c.2026A>G & c.2032T>A) into the endogenous APP locus. The Swedish mutation is a well-characterized familial Alzheimer’s disease mutation associated with increased β-secretase cleavage of APP, leading to an elevated production of amyloid-β peptides and early-onset Alzheimer’s pathology (Sasaguri et al.; Thordardottir & Graff).
This product’s parental human induced pluripotent stem cell (hiPSC) line, Healthy Control Human iPSC Line, Female, SCTi003-A, is a well-characterized control line derived from peripheral blood mononuclear cells (PBMCs) from a 48-year-old donor. Targeted gene modifications were confirmed by Sanger sequencing. Post-editing, extensive quality control procedures were undertaken in the manufacturing process for SCTi003-A-2 to ensure optimal product performance and reproducibility. SCTi003-A-2 is karyotypically stable, expresses markers of the undifferentiated state, and remains capable of directed differentiation into all three germ layers, including neural lineage cells relevant for Alzheimer’s disease research. This genome-edited hiPSC line, along with its parental hiPSC line, provides a robust, isogenic disease modeling tool for studying amyloidogenic processing, studying Alzheimer’s disease mechanisms, and evaluating therapeutic interventions targeting the APP pathway. SCTi003-A-2 is manufactured with mTeSRTM Plus (Catalog #100-0276) and is compatible with STEMdiffTM cell culture media products, allowing for standardized high-quality maintenance and differentiation to various cell types, such as neurons, astrocytes, and microglia. Cells were obtained using Institutional Review Board (IRB)-approved consent forms and protocols. |
| User feedback | |
Provider |
|
| Generator |
STEMCELL Technologies Inc. (SCT)
Contact:
STEMCELL Technologies Inc. (SCT) |
| Owner | STEMCELL Technologies Inc. (SCT) |
| Distributors | |
External Databases |
|
| BioSamples | SAMEA119562656 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: allowed
|
| Subclone of | |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
SCTi003-A.
|
Login to share your feedback, experiences or results with the research community.